{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Immunic, Inc. technically bullish or bearish?
As of May 19, 2025, Immunic, Inc. is in a bearish trend, indicated by bearish MACD, Bollinger Bands, moving averages, and KST across multiple timeframes, suggesting a continued weakness in the stock.
Who are in the management team of Immunic, Inc.?
As of March 2022, the management team of Immunic, Inc. includes Dr. Daniel Vitt as President and CEO, along with independent directors Ms. Tamar Howson, Dr. Jorg Neermann, Dr. Vincent Ossipow, Mr. Barclay Phillips, and Mr. Jan Van den Bossche.
What does Immunic, Inc. do?
Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral therapies for chronic inflammatory and autoimmune diseases. As of March 2025, it has a market cap of $73.54 million and reported a net profit of -$25 million.
How big is Immunic, Inc.?
As of Jun 18, Immunic, Inc. has a market capitalization of 73.54 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -96.40 million over the latest four quarters. Shareholder's funds are 18.43 million, and total assets are 40.87 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
